Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS.  ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.